Analytes/procedures in bold
type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
Survey FL9 is intended for laboratories that currently or will begin to perform minimal residual disease (MRD) testing (rare event analysis) for plasma cell myeloma.
- Two 4.5‑mL specimens containing a cell line/whole blood mixture simulating plasma cell myeloma minimal residual desease
- One case with clinical history and gated dot plots
- Shipment A: May 24
- Shipment B: November 29